Breaking: Is Protagonist Therapeutics Inc a Buy? The Stock Reaches 52-Week High Today

Breaking: Is Protagonist Therapeutics Inc a Buy? The Stock Reaches 52 Week High Today

The stock of Protagonist Therapeutics Inc (NASDAQ:PTGX) hit a new 52-week high and has $27.01 target or 8.00% above today’s $25.01 share price. The 7 months bullish chart indicates low risk for the $424.19 million company. The 1-year high was reported on Nov, 28 by Barchart.com. If the $27.01 price target is reached, the company will be worth $33.94 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock decreased 1.88% or $0.48 during the last trading session, hitting $25.01. About 19,566 shares traded hands. Protagonist Therapeutics Inc (NASDAQ:PTGX) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.

Analysts await Protagonist Therapeutics Inc (NASDAQ:PTGX) to report earnings on February, 13. After $-0.87 actual earnings per share reported by Protagonist Therapeutics Inc for the previous quarter, Wall Street now forecasts -33.33% EPS growth.

According to Zacks Investment Research, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.”

More notable recent Protagonist Therapeutics Inc (NASDAQ:PTGX) news were published by: Prnewswire.com which released: “Protagonist Therapeutics Reports Third Quarter 2016 Financial Results and …” on November 14, 2016, also Prnewswire.com with their article: “Protagonist Therapeutics Announces Pricing of Initial Public Offering” published on August 11, 2016, Wsj.com published: “Protagonist Therapeutics Discloses IPO Plans” on July 11, 2016. More interesting news about Protagonist Therapeutics Inc (NASDAQ:PTGX) were released by: Prnewswire.com and their article: “William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board” published on July 08, 2016 as well as Prnewswire.com‘s news article titled: “Protagonist Therapeutics to Present New Data for PTG-100 and PTG-200 at …” with publication date: May 17, 2016.

PTGX Company Profile

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Firm has a technology platform focused on discovering and developing peptide new chemical entities (NCEs) to address unmet medical needs. Protagonist’s primary focus is on developing oral peptide drugs that specifically target biological pathways. The Company’s oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company’s initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn’s disease (CD). Protagonist’s product candidate beyond IBD is PTG-300, an injectable hepcidin mimetic.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment